NASDAQ:TSHA Taysha Gene Therapies (TSHA) Stock Forecast, Price & News $0.79 +0.04 (+5.33%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$0.73▼$0.7950-Day Range$0.64▼$0.8752-Week Range$0.61▼$5.09Volume283,913 shsAverage Volume255,682 shsMarket Capitalization$50.70 millionP/E RatioN/ADividend YieldN/APrice Target$8.46 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Taysha Gene Therapies MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside941.9% Upside$8.23 Price TargetShort InterestHealthy3.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$3,400 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.87) to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.52 out of 5 starsMedical Sector121st out of 983 stocksBiological Products, Except Diagnostic Industry15th out of 164 stocks 4.4 Analyst's Opinion Consensus RatingTaysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 10 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.23, Taysha Gene Therapies has a forecasted upside of 941.9% from its current price of $0.79.Amount of Analyst CoverageTaysha Gene Therapies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.23% of the float of Taysha Gene Therapies has been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Taysha Gene Therapies has recently decreased by 31.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSHA. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 2 people have searched for TSHA on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,400.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.20% of the stock of Taysha Gene Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.12% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Taysha Gene Therapies are expected to grow in the coming year, from ($0.87) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Taysha Gene Therapies (NASDAQ:TSHA) StockTaysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.Read More Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address TSHA Stock News HeadlinesMay 20, 2023 | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Rating of "Moderate Buy" by AnalystsMay 19, 2023 | finance.yahoo.comTaysha Gene Therapies Touts Encouraging Preclinical Data From Rett Syndrome CandidateJune 3, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 19, 2023 | finance.yahoo.comTaysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual MeetingMay 16, 2023 | finance.yahoo.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2023 Earnings Call TranscriptMay 15, 2023 | markets.businessinsider.comRobert W. Baird Sticks to Its Buy Rating for Taysha Gene Therapies (TSHA)May 12, 2023 | markets.businessinsider.comJMP Securities Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)May 12, 2023 | finance.yahoo.comQ1 2023 Taysha Gene Therapies Inc Earnings CallJune 3, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 11, 2023 | finance.yahoo.comTaysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 7, 2023 | americanbankingnews.comHead-To-Head Contrast: Taysha Gene Therapies (NASDAQ:TSHA) and Sorrento Therapeutics (NASDAQ:SRNE)May 4, 2023 | finance.yahoo.comTaysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11April 29, 2023 | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Short Interest Down 15.5% in AprilApril 27, 2023 | bizjournals.comOuch! Another gene therapy setback as biotech halts 200-job Durham facilityApril 27, 2023 | bizjournals.comAnother gene therapy setback as biotech halts 200-job Durham facilityApril 27, 2023 | finance.yahoo.comTaysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual MeetingApril 25, 2023 | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesApril 18, 2023 | americanbankingnews.comShort Interest in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Declines By 18.2%April 15, 2023 | finance.yahoo.comEven after rising 30% this past week, Taysha Gene Therapies (NASDAQ:TSHA) shareholders are still down 84% over the past yearApril 5, 2023 | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of "Moderate Buy" by BrokeragesApril 2, 2023 | americanbankingnews.comJMP Securities Reaffirms Market Outperform Rating for Taysha Gene Therapies (NASDAQ:TSHA)April 2, 2023 | americanbankingnews.comTaysha Gene Therapies, Inc. Expected to Post Q1 2023 Earnings of ($0.39) Per Share (NASDAQ:TSHA)April 1, 2023 | americanbankingnews.comChardan Capital Trims Taysha Gene Therapies (NASDAQ:TSHA) Target Price to $5.00April 1, 2023 | americanbankingnews.comTruist Financial Lowers Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $3.00March 31, 2023 | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Rating Reiterated by Needham & Company LLCMarch 30, 2023 | americanbankingnews.comCantor Fitzgerald Lowers Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $2.00March 29, 2023 | markets.businessinsider.comChardan Capital Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)See More Headlines TSHA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSHA Company Calendar Last Earnings3/28/2023Today6/03/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TSHA CUSIPN/A CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees38Year Founded2020Price Target and Rating Average Stock Price Forecast$8.23 High Stock Price Forecast$19.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+971.1%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($2.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-166,010,000.00 Net MarginsN/A Pretax Margin-1,849.60% Return on Equity-1,790.06% Return on Assets-110.88% Debt Debt-to-Equity Ratio40.01 Current Ratio1.33 Quick Ratio1.33 Sales & Book Value Annual Sales$2.50 million Price / Sales20.28 Cash FlowN/A Price / Cash FlowN/A Book Value($0.23) per share Price / Book-3.43Miscellaneous Outstanding Shares64,180,000Free Float55,707,000Market Cap$50.70 million OptionableNot Optionable Beta1.17 Social Links Key ExecutivesMr. R. A. Session II (Age 43)Founder, Pres, CEO & Director Comp: $542.95kMr. Kamran Alam CPA (Age 44)M.B.A., Chief Financial Officer Comp: $395.51kDr. Suyash Prasad FFPM (Age 52)M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M, Chief Medical Officer and Head of R&D Comp: $617.34kMr. Frederick Porter Ph.D.Chief Technical OfficerMr. Jim RouseChief Information OfficerMs. Tracy M. PorterChief People OfficerMs. Emily McGinnis M.P.H.Chief Patient Officer & Head of Gov. AffairsMs. Mishima GerhartChief Regulatory Officer & Head of QualityMr. Sean McAuliffeChief Commercial OfficerMr. Greg GaraSr. VP of ManufacturingMore ExecutivesKey CompetitorsSAB BiotherapeuticsNASDAQ:SABSGreenLight BiosciencesNASDAQ:GRNACortexymeNASDAQ:CRTXCandel TherapeuticsNASDAQ:CADLCardiol TherapeuticsNASDAQ:CRDLView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 44,723 shares on 5/16/2023Ownership: 0.587%Susquehanna International Group LLPSold 47,980 shares on 5/16/2023Ownership: 0.156%Sukumar NagendranBought 5,000 shares on 5/16/2023Total: $3,400.00 ($0.68/share)XTX Topco LtdBought 85,167 shares on 5/15/2023Ownership: 0.133%Renaissance Technologies LLCSold 270,200 shares on 5/12/2023Ownership: 0.389%View All Insider TransactionsView All Institutional Transactions TSHA Stock - Frequently Asked Questions Should I buy or sell Taysha Gene Therapies stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TSHA shares. View TSHA analyst ratings or view top-rated stocks. What is Taysha Gene Therapies' stock price forecast for 2023? 14 brokerages have issued 12-month price targets for Taysha Gene Therapies' shares. Their TSHA share price forecasts range from $2.00 to $19.00. On average, they expect the company's share price to reach $8.23 in the next year. This suggests a possible upside of 941.9% from the stock's current price. View analysts price targets for TSHA or view top-rated stocks among Wall Street analysts. How have TSHA shares performed in 2023? Taysha Gene Therapies' stock was trading at $2.26 at the start of the year. Since then, TSHA shares have decreased by 65.0% and is now trading at $0.79. View the best growth stocks for 2023 here. Are investors shorting Taysha Gene Therapies? Taysha Gene Therapies saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 1,190,000 shares, a drop of 31.2% from the April 30th total of 1,730,000 shares. Based on an average trading volume of 401,900 shares, the short-interest ratio is currently 3.0 days. Currently, 3.2% of the company's stock are short sold. View Taysha Gene Therapies' Short Interest. When is Taysha Gene Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our TSHA earnings forecast. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced its quarterly earnings data on Tuesday, March, 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by $0.58. The company had revenue of $2.50 million for the quarter. When did Taysha Gene Therapies IPO? (TSHA) raised $125 million in an initial public offering (IPO) on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager. What is Taysha Gene Therapies' stock symbol? Taysha Gene Therapies trades on the NASDAQ under the ticker symbol "TSHA." Who are Taysha Gene Therapies' major shareholders? Taysha Gene Therapies' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (4.81%), Acadian Asset Management LLC (0.63%), BlackRock Inc. (0.62%), Geode Capital Management LLC (0.59%), Quantum Private Wealth LLC (0.56%) and Renaissance Technologies LLC (0.39%). Insiders that own company stock include Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II, Sean P Nolan, Sukumar Nagendran and Suyash Prasad. View institutional ownership trends. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Taysha Gene Therapies' stock price today? One share of TSHA stock can currently be purchased for approximately $0.79. How much money does Taysha Gene Therapies make? Taysha Gene Therapies (NASDAQ:TSHA) has a market capitalization of $50.70 million and generates $2.50 million in revenue each year. The company earns $-166,010,000.00 in net income (profit) each year or ($2.75) on an earnings per share basis. How can I contact Taysha Gene Therapies? Taysha Gene Therapies' mailing address is 2280 Inwood Road, DALLAS TX, 75235. The official website for the company is www.tayshagtx.com. The company can be reached via phone at 214-612-0000 or via email at investors@tayshagtx.com. This page (NASDAQ:TSHA) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.